Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 13/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5092195 | 0.88 | HSD11B1 (0.78) | HSD11B1NR1I2SMN1; SMN2HTT | |
| SCHEMBL5104997 | 0.87 | HSD11B1 (0.77) | HSD11B1 | |
| SCHEMBL5105117 | 0.85 | HSD11B1 (0.74) | HSD11B1TSHR | |
| SCHEMBL5098612 | 0.85 | HSD11B1 (0.74) | HSD11B1NR1I2 | |
| SCHEMBL5095896 | 0.85 | HSD11B1 (0.74) | HSD11B1NR1I2 | |
| SCHEMBL14301752 | 0.85 | HSD11B1 (0.74) | HSD11B1NR1I2 | |
| SCHEMBL5092167 | 0.84 | HSD11B1 (0.71) | HSD11B1NR1I2 | |
| SCHEMBL5104995 | 0.83 | HSD11B1 (0.71) | HSD11B1NR1I2MAPK1 | |
| SCHEMBL5095961 | 0.83 | HSD11B1 (0.71) | HSD11B1DRD2 | |
| SCHEMBL5098044 | 0.83 | HSD11B1 (0.71) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10894054-B2 | FXR agonist compositions for combination therapy | INTERCEPT PHARMACEUTICALS, INC. (US) | 2021-01-19 | — | — | US | disclosed |
| US-10039772-B2 | Methods and compositions for treating alcohol use disorders | SANNA PIETRO PAOLO (US) | 2018-08-07 | — | — | US | disclosed |
| US-10039772-B2 | Methods and compositions for treating alcohol use disorders | SANNA PIETRO PAOLO (US) | 2018-08-07 | — | — | US | disclosed |
| US-20180117065-A1 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | INTERCEPT PHARMACEUTICALS, INC. | 2018-05-03 | — | — | US | disclosed |
| US-20180117065-A1 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | INTERCEPT PHARMACEUTICALS, INC. | 2018-05-03 | — | — | US | disclosed |
| US-20170232007-A1 | METHODS AND COMPOSITIONS FOR TREATING ALCOHOL USE DISORDERS | SANNA PIETRO PAOLO (US) | 2017-08-17 | — | — | US | disclosed |
| US-20170232007-A1 | METHODS AND COMPOSITIONS FOR TREATING ALCOHOL USE DISORDERS | SANNA PIETRO PAOLO (US) | 2017-08-17 | — | — | US | disclosed |
| US-7329683-B2 | 11-β-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK & CO., INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329683-B2 | 11-β-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK & CO., INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329683-B2 | 11-β-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK & CO., INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-20070099884-A1 | Combination therapy for the treatment of diabetes | MERCK & CO., INC. | 2007-05-03 | — | — | US | disclosed |
| US-20070099884-A1 | Combination therapy for the treatment of diabetes | MERCK & CO., INC. | 2007-05-03 | — | — | US | disclosed |
| US-20050070720-A1 | 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK SHARP & DOHME CORP. | 2005-03-31 | — | — | US | disclosed |
| WO-2004110375-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES | MERCK & CO., INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10039772-B2 | Methods and compositions for treating alcohol use disorders | HSD3B1, HSD11B1, HSD3B2 | HSD11B1 2/4885NR1I2 62/4885TSHR 3476/4885 |
| US-10894054-B2 | FXR agonist compositions for combination therapy | GPR119, FXR1, NR1H4 | HSD11B1 241/4885NR1I2 64/4885TSHR 357/4885 |
| US-20170232007-A1 | METHODS AND COMPOSITIONS FOR TREATING ALCOHOL USE DISORDERS | HSD3B1, HSD11B1, HSD3B2 | HSD11B1 2/4885NR1I2 62/4885TSHR 3476/4885 |
| US-20180117065-A1 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | GPR119, FABP1, SLC10A1 | HSD11B1 214/4885NR1I2 149/4885TSHR 833/4885 |
| US-20070099884-A1 | Combination therapy for the treatment of diabetes | GPR119, FABP4, IAPP | HSD11B1 412/4885NR1I2 2476/4885TSHR 4250/4885 |
| US-20050070720-A1 | 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885NR1I2 129/4885TSHR 2731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.